Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.
Lloyd KA, Moore AR, Parsons BN, O’Hara A, Boyce M, Dockray GJ, Varro A and Pritchard DM. Gastrin-induced [...]
Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
Boyce M and Thomsen L. Gastric neuroendocrine tumours: prevalence in Europe, USA, and Japan, and rationale for [...]
Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M, Dowen S, Turnbull G, van den Berg F, Zhao C-M, Chen D, Black JW. Effect [...]
Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Moore A, Boyce M, Steele I, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, [...]
The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
Sordal Ø, Waldum H, Nordrum I, Boyce, M, Bergh K, Munkvold B, Qvigstad G. The gastrin receptor [...]
Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M, Warrington S, Black JW. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the [...]